EYPT EyePoint Pharmaceuticals Inc.

1.5
-0.01  -1%
Previous Close 1.51
Open 1.51
Price To Book 7.89
Market Cap 159,105,539
Shares 106,105,728
Volume 14,035
Short Ratio
Av. Daily Volume 444,339

NewsSee all news

  1. EyePoint Pharmaceuticals Appoints Wendy DiCicco, CPA, to Board of Directors
  2. EyePoint Pharmaceuticals, Inc. - U.S. Commercialization of DEXYCU® (dexamethasone intraocular suspension) 9%
  3. EyePoint Pharmaceuticals Added to Russell 3000® and 2000® Indexes
  4. Hedge Funds Have Never Been This Bullish On EyePoint Pharmaceuticals, Inc. (EYPT)
  5. EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema
FDA approval announced October 15, 2018.
YUTIQ
Non-infectious uveitis
sNDA filing due 2019 for 6-month formulation.
Yutiq
Non-infectious uveitis

Latest News

  1. EyePoint Pharmaceuticals Appoints Wendy DiCicco, CPA, to Board of Directors
  2. EyePoint Pharmaceuticals, Inc. - U.S. Commercialization of DEXYCU® (dexamethasone intraocular suspension) 9%
  3. EyePoint Pharmaceuticals Added to Russell 3000® and 2000® Indexes
  4. Hedge Funds Have Never Been This Bullish On EyePoint Pharmaceuticals, Inc. (EYPT)
  5. EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  6. EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires
  7. Edited Transcript of EYPT earnings conference call or presentation 8-May-19 12:30pm GMT
  8. EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
  9. EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue Estimates
  10. EyePoint Pharmaceuticals: 1Q Earnings Snapshot
  11. EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
  12. Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know
  13. EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  14. EyePoint Pharmaceuticals Announces First Quarter 2019 Financial Results Release Date and Conference Call Information
  15. EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences
  16. Here's Why EyePoint Pharmaceuticals Saw Its Share Price Drop Today
  17. EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  18. EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
  19. Edited Transcript of EYPT earnings conference call or presentation 14-Mar-19 12:30pm GMT